MBL

(redirected from Menstrual Blood Loss)
AcronymDefinition
MBLMacquarie Bank Limited
MBLMobile
MBLMarine Biological Laboratory
MBLMedical & Biological Laboratories (Japan)
MBLMannose-Binding Lectin
MBLMaster of Business Leadership (various locations)
MBLMetro Baseball League (various locations)
MBLMortgage Broker/Lender (license)
MBLMaster Business License
MBLMsn Back Links
MBLMicrosoft Business License
MBLModel-Based Library
MBLMember Business Lending (credit unions)
MBLMarine Boundary Layer
MBLMetallo Beta Lactamase
MBLMovimiento Bolivia Libre (Movement Free Bolivia)
MBLMolecular Biology Laboratory
MBLMenstrual Blood Loss
MBLMonoclonal B-Cell Lymphocytosis
MBLMinimum Breaking Load (wire rope specification)
MBLMountain Bike Leader
MBLMold & Bacteria Consulting Laboratories (Canada)
MBLMean Breaking Load
MBLMaster Bill of Lading (shipping/logistics)
MBLManistee, MI, USA - Manistee Blacker Airport (Airport Code)
MBLMontebello Bus Lines (Montebello, CA)
MBLMaximum Broken Load
MBLMarried But Looking
MBLMensa Belgium-Luxemburg
MBLMinimum Baseline
MBLMassachusetts Bay Lines
MBLMain Bitline (computer memory)
MBLMean Burst Location (artillery; US DoD)
MBLMaximum Branching Level
MBLMieter- und Bürgerliste (Local Party in Halle, Germany)
MBLMain Battle Line
References in periodicals archive ?
Nevertheless, ormeloxifene antagonize estrogen in uterus (endometrium), breast tissues which result in endometrial atrophy to decreases menstrual blood loss. [4-6]
Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area.
Conclusion: The levonorgestrel intrauterine system was better than norethisterone with marked clinical benefit of profound reduction in menstrual blood loss.
Stewart A et al conducted a study to determine whether the levonorgestrel-releasing device (LNG-IUS) licensed at present for contraceptive use, may reduce menstrual blood loss with few side effects.
In women, poor dietary intake and menstrual blood loss are the most common causes.
Galen and colleagues performed a retrospective analysis of these same patients, demonstrating that RFVTA of intramural fibroids without submucosal components leads to a clinically and statistically significant reduction in menstrual blood loss. (30)
We used oral tranexamic acid in all patients and it reduced menstrual blood loss. Oral tranexamic acid (20-25 mg/kg every 8 11; generally a 1000-mg dose) for 5-7 days of the menstrual cycle was our practice.
There was no statistically significant relationship between demographic status and menstrual blood loss, and mean blood loss at baseline was similar in the three study groups, ranging from 117.6 to 121.2 ml per menstrual cycle (p>0.05 between groups) (Table 2).
Studies gauging the effectiveness of treatments for menorrhagia have focused on their control of menstrual blood loss, but there is great discordance between objective measures of blood loss and women's perception of the amount they bleed.
The study was a randomized double-blinded control study designed to evaluate the effect of 400 mg of Noni twice daily compared with placebo on pain and menstrual blood loss in the treatment of primary dysmenorrhoea.
In the current analysis of data pooled from both studies, reductions in menstrual blood loss tended to be greater with increasing patient age.
Quantitatively defined as blood loss [greater than or equal to] 80 mL per cycle, heavy menstrual bleeding can also be diagnosed based on a patient's perception of menstrual blood loss and its effect on her daily life.